Nevanac 3-Month Safety Study With QID Dosing

Last updated: March 1, 2012
Sponsor: Alcon Research
Overall Status: Completed

Phase

3

Condition

Eye Disorders/infections

Vision Loss

Eye Disease

Treatment

N/A

Clinical Study ID

NCT00332774
C-05-20
  • Ages > 10
  • All Genders

Study Summary

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients of any race or sex ages 10 years or older undergoing cataract extraction withplanned implantation of a posterior chamber intraocular lens.

  • Other protocol-defined inclusion criteria may apply.

Exclusion

Exclusion Criteria:

  • Under 10

  • Other protocol-defined exclusion criteria may apply

Study Design

Total Participants: 149
Study Start date:
February 01, 2006
Estimated Completion Date:
December 31, 2006

Connect with a study center

  • Contact Alcon for Trial Locations

    Fort Worth, Texas 76134
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.